Cargando…

Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review

Sensitivity to endocrine therapy of patients with estrogen receptor (ER)-positive metastatic breast cancer and germline BRCA1/2 mutations is not yet fully elucidated. Furthermore, the registration trials of CDK 4/6 inhibitors in combination with endocrine therapy lacked of a pre-specified subgroup a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Militello, Anna Maria, Zielli, Teresa, Boggiani, Daniela, Michiara, Maria, Naldi, Nadia, Bortesi, Beatrice, Zanelli, Paola, Uliana, Vera, Giuliotti, Sara, Musolino, Antonino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700293/ https://www.ncbi.nlm.nih.gov/pubmed/31456944 http://dx.doi.org/10.3389/fonc.2019.00759

Ejemplares similares

Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers
por: Tommasi, Chiara, et al.
Publicado: (2021)

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer
por: Viansone, A., et al.
Publicado: (2022)

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin
por: Tiseo, M, et al.
Publicado: (2013)

Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review
por: Pellegrino, Benedetta, et al.
Publicado: (2017)

Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
por: Pellegrino, B., et al.
Publicado: (2020)

BRCA1 And Estrogen/Estrogen Receptor In Breast Cancer: Where They Interact?
por: Wang, Li, et al.
Publicado: (2014)

More dissimilarities than affinities between DNAJB11-PKD and ADPKD
por: Pisani, Isabella, et al.
Publicado: (2022)

Transactivation of the estrogen receptor promoter by BRCA1
por: Archey, William B., et al.
Publicado: (2017)

Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation
por: Pujol, Pascal, et al.
Publicado: (2022)

Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
por: Wang, Chuying, et al.
Publicado: (2018)

COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION
por: Johnson, Neil, et al.
Publicado: (2011)

Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers
por: Litwiniuk, Maria M, et al.
Publicado: (2008)

Estrogen receptor transcription and transactivation: Genetic modifiers of cancer risks conferred by BRCA1 and BRCA2
por: Devilee, P
Publicado: (2001)

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
por: Aziz, Diar, et al.
Publicado: (2021)

Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study
por: Buti, Sebastiano, et al.
Publicado: (2021)

Breast Cancer in Italy: Stage and Region Distribution
por: Mangone, Lucia, et al.
Publicado: (2022)

Estrogen-repressed genes – key mediators of estrogen action?
por: Zubairy, Simeen, et al.
Publicado: (2005)

DNA stabilization by the upregulation of estrogen signaling in BRCA gene mutation carriers
por: Suba, Zsuzsanna
Publicado: (2015)

Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer
por: McDermott, Martina S.J., et al.
Publicado: (2017)

Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
por: Cesari, Eleonora, et al.
Publicado: (2023)

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
por: Scheidemann, Erin R., et al.
Publicado: (2021)

Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells
por: Kavarthapu, Raghuveer, et al.
Publicado: (2017)

Estrogen receptor transcription and transactivation: Basic aspects of estrogen action
por: Nilsson , Stefan, et al.
Publicado: (2000)

Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
por: Tung, Nadine, et al.
Publicado: (2010)

Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?
por: Lakhani, Sunil R, et al.
Publicado: (2010)

POTENTIAL CONSEQUENCES OF THE BRCA1 MUTATION CARRIER STATE ON ESTROGEN RESPONSIVE ORGANS
por: Yen, Hai-Yun, et al.
Publicado: (2012)

Influence of Sex and Age on Site of Onset, Morphology, and Site of Metastasis in Colorectal Cancer: A Population-Based Study on Data from Four Italian Cancer Registries
por: Perotti, Viviana, et al.
Publicado: (2023)

Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers
por: Vocka, Michal, et al.
Publicado: (2019)

CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival
por: Minguillón, Jordi, et al.
Publicado: (2022)

The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities
por: Zielli, Teresa, et al.
Publicado: (2023)

The other estrogen receptor in the plasma membrane: implications for the actions of environmental estrogens.
por: Watson, C S, et al.
Publicado: (1995)

A transcriptomics model of estrogen action in the ovine fetal hypothalamus: evidence for estrogenic effects of ICI 182,780
por: Rabaglino, Maria Belen, et al.
Publicado: (2018)

Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma
por: Mazzaschi, Giulia, et al.
Publicado: (2022)

The Leukemogenic Action of Estrogens in Hybrid Mice
por: Gardner, W. U., et al.
Publicado: (1944)

Estrogen Biosynthesis and Action in Ovarian Cancer
por: Mungenast, Felicitas, et al.
Publicado: (2014)

Molecular Pathways of Estrogen Receptor Action
por: Pakdel, Farzad
Publicado: (2018)

A DNA Repair BRCA1 Estrogen Receptor and Targeted Therapy in Breast Cancer
por: Ratanaphan, Adisorn
Publicado: (2012)

Inhibition of Estrogen Signaling Reduces the Incidence of BRCA1-associated Mammary Tumor Formation
por: Baek, Hye Jung, et al.
Publicado: (2018)

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
por: Finn, Richard S., et al.
Publicado: (2016)

Heterogeneity in conservation of multifunctional partner enzymes with meiotic importance, CDK2 kinase and BRCA1 ubiquitin ligase
por: Matveevsky, Sergey, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d8icnmdr1gb7ilsnr6bvsu2a98